Evidence map›Paper›PMID 36448002›Full record

ArticleInternational journal of clinical practice2022

Longitudinal Relationship between the Introduction of Medicinal Cannabis and Polypharmacy: An Australian Real-World Evidence Study.

Maja Kalaba, Graham M L Eglit, Matthew T Feldner, Patrizia D Washer, Tracie Ernenwein, Alistair W Vickery, Mark A Ware

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maja KalabaCanopy Growth Corporation, 1 Hershey Drive, Smiths Falls, ON K7A 3K8, Canada.
Graham M L EglitCanopy Growth Corporation, 1 Hershey Drive, Smiths Falls, ON K7A 3K8, Canada.
Matthew T FeldnerCanopy Growth Corporation, 1 Hershey Drive, Smiths Falls, ON K7A 3K8, Canada.ORCID https://orcid.org/0000-0002-7299-9058
Patrizia D WasherEmyria Limited, D2 661 Newcastle Street, Leederville WA 6007, PO Box 1442, West Leederville, WA 6901, Australia.
Tracie ErnenweinEmyria Limited, D2 661 Newcastle Street, Leederville WA 6007, PO Box 1442, West Leederville, WA 6901, Australia.
Alistair W VickeryEmyria Limited, D2 661 Newcastle Street, Leederville WA 6007, PO Box 1442, West Leederville, WA 6901, Australia.
Mark A WareCanopy Growth Corporation, 1 Hershey Drive, Smiths Falls, ON K7A 3K8, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Recent studies recommend medicinal cannabis (MC) as a potential treatment for chronic pain (CP) when conventional therapies are not successful; however, data from Australia is limited. This real-world evidence study explored how the introduction of MC related to concomitant medication use over time. Long-term safety also was examined. Methods: Data were collected by the Emerald Clinics (a network of seven clinics located across Australia) as part of routine practice from Jan 2020 toJan 2021. Medications were classified by group: antidepressants, benzodiazepines, nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and total number of medications. Adverse events (AEs) were collected at each visit and subsequently coded using the Medical Dictionary for Regulatory Activities version 23 into the system organ class (SOC) and preferred term (PT). A total of 535 patients were analyzed. Results: The most common daily oral dose was 10 mg for delta-9-tetrahydrocannabinol (THC) and 15 mg for cannabidiol (CBD). With the introduction of MC, patients' total number of medications consumed decreased over the course of one year; significant reductions in NSAIDs, benzodiazepines, and antidepressants were observed (

Indexed as

Medical MarijuanaAnalgesics, OpioidAnti-Inflammatory Agents, Non-SteroidalAustraliaBenzodiazepinesHumansPolypharmacyAnalgesics, OpioidAnti-Inflammatory Agents, Non-SteroidalBenzodiazepinesMedical Marijuana

Identifiers

PMID36448002
PMCPMC9663249
OpenAlexW4308466872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.